{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:46:07Z","timestamp":1792025167084,"version":"4.4.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI166969"],"award-info":[{"award-number":["R01AI166969"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI129703"],"award-info":[{"award-number":["R01AI129703"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI154559"],"award-info":[{"award-number":["R01AI154559"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000052","name":"U.S. Department of Health & Human Services | NIH | NIH Office of the Director","doi-asserted-by":"publisher","award":["K01 OD036063"],"award-info":[{"award-number":["K01 OD036063"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Microbiol"],"DOI":"10.1038\/s41564-026-02444-x","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T16:01:51Z","timestamp":1786377711000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combination therapy with broadly neutralizing antibodies, antiretroviral therapy and CCR5 blockade limits viral reservoir seeding in infant macaque model of HIV"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7633-3122","authenticated-orcid":false,"given":"Jonah B.","family":"Sacha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Ordonez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpi","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8985-6192","authenticated-orcid":false,"given":"Philip","family":"Barnette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cleiton","family":"Pessoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Humkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0731-2523","authenticated-orcid":false,"given":"Anden","family":"Morehead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer K.","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodie L.","family":"Usachenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9870-2982","authenticated-orcid":false,"given":"Shrivaas","family":"Vijayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Altair","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Sidener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4059-7318","authenticated-orcid":false,"given":"Anne D.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Pastenkos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohita","family":"Ojha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Barber-Axthelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bella","family":"Swan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachele","family":"Bochart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Mascola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amarendra","family":"Pegu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5850-6237","authenticated-orcid":false,"given":"Emily J.","family":"Fray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael M.","family":"Wolters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6712-3775","authenticated-orcid":false,"given":"Janet D.","family":"Siliciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1764-1993","authenticated-orcid":false,"given":"Robert F.","family":"Siliciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott G.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7375-1337","authenticated-orcid":false,"given":"Koen K. A.","family":"Van Rompay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann J.","family":"Hessell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1477-9575","authenticated-orcid":false,"given":"Nancy L.","family":"Haigwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"2444_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1093\/infdis\/jiv219","volume":"212","author":"JM Siliciano","year":"2015","unstructured":"Siliciano, J. M. & Siliciano, R. F. The remarkable stability of the latent reservoir for HIV-1 in resting memory CD4+ T cells. J. Infect. Dis. 212, 1345\u20131347 (2015).","journal-title":"J. Infect. Dis."},{"key":"2444_CR2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11904-020-00495-1","volume":"17","author":"SJ Berendam","year":"2020","unstructured":"Berendam, S. J. et al. Pediatric HIV: the potential of immune therapeutics to achieve viral remission and functional cure. Curr. HIV\/AIDS Rep. 17, 237\u2013248 (2020).","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"2444_CR3","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/COH.0000000000000938","volume":"20","author":"I Mallik","year":"2025","unstructured":"Mallik, I., Henderson, M., Fidler, S. & Foster, C. Aging of adult lifetime survivors with perinatal HIV. Curr. Opin. HIV AIDS 20, 379\u2013387 (2025).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"2444_CR4","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/imr.12511","volume":"275","author":"A Pegu","year":"2017","unstructured":"Pegu, A., Hessell, A. J., Mascola, J. R. & Haigwood, N. L. Use of broadly neutralizing antibodies for HIV-1 prevention. Immunol. Rev. 275, 296\u2013312 (2017).","journal-title":"Immunol. Rev."},{"key":"2444_CR5","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","volume":"384","author":"L Corey","year":"2021","unstructured":"Corey, L. et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N. Engl. J. Med. 384, 1003\u20131014 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2444_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/COH.0000000000000927","volume":"20","author":"RL Shapiro","year":"2025","unstructured":"Shapiro, R. L., Masheto, G. & Ajibola, G. Use of broadly neutralizing antibodies in pediatric HIV for treatment and remission. Curr. Opin. HIV AIDS 20, 279\u2013286 (2025).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"2444_CR7","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/s41591-018-0186-4","volume":"24","author":"Y Bar-On","year":"2018","unstructured":"Bar-On, Y. et al. Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nat. Med. 24, 1701\u20131707 (2018).","journal-title":"Nat. Med."},{"key":"2444_CR8","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1038\/s41591-024-03247-5","volume":"30","author":"B Julg","year":"2024","unstructured":"Julg, B. et al. Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1\/2a trial. Nat. Med. 30, 3534\u20133543 (2024).","journal-title":"Nat. Med."},{"key":"2444_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/QAI.0000000000003648","volume":"99","author":"JC Gathe","year":"2025","unstructured":"Gathe, J. C. et al. Leronlimab Treatment for Multidrug-Resistant HIV-1 (OPTIMIZE): a randomized, double-blind, placebo-controlled trial. JAIDS J. Acquir. Immune Defic. Syndr. 99, 185\u2013194 (2025).","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"2444_CR10","doi-asserted-by":"publisher","unstructured":"Yang, B. et al. Clinical characteristics and outcomes of coronavirus disease 2019 patients who received compassionate-use leronlimab. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa1583 (2020).","DOI":"10.1093\/cid\/ciaa1583"},{"key":"2444_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23697-6","volume":"12","author":"XL Chang","year":"2021","unstructured":"Chang, X. L. et al. Antibody-based CCR5 blockade protects macaques from mucosal SHIV transmission. Nat. Commun. 12, 3343 (2021).","journal-title":"Nat. Commun."},{"key":"2444_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.chom.2019.06.005","volume":"26","author":"AM Bender","year":"2019","unstructured":"Bender, A. M. et al. The landscape of persistent viral genomes in ART-treated SIV, SHIV, and HIV-2 infections. Cell Host Microbe 26, 73\u201385 e4 (2019).","journal-title":"Cell Host Microbe"},{"key":"2444_CR13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/nature13594","volume":"512","author":"JB Whitney","year":"2014","unstructured":"Whitney, J. B. et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 512, 74\u201377 (2014).","journal-title":"Nature"},{"key":"2444_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1012135","volume":"20","author":"BF Keele","year":"2024","unstructured":"Keele, B. F. et al. Early antiretroviral therapy in SIV-infected rhesus macaques reveals a multiphasic, saturable dynamic accumulation of the rebound competent viral reservoir. PLoS Pathog. 20, e1012135 (2024).","journal-title":"PLoS Pathog."},{"key":"2444_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07881-9","volume":"9","author":"JB Whitney","year":"2018","unstructured":"Whitney, J. B. et al. Prevention of SIVmac251 reservoir seeding in rhesus monkeys by early antiretroviral therapy. Nat. Commun. 9, 5429 (2018).","journal-title":"Nat. Commun."},{"key":"2444_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/science.adn5866","volume":"385","author":"FNN Pitchai","year":"2024","unstructured":"Pitchai, F. N. N. et al. Engineered deletions of HIV replicate conditionally to reduce disease in nonhuman primates. Science 385, eadn5866 (2024).","journal-title":"Science"},{"key":"2444_CR17","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1128\/JVI.01759-06","volume":"81","author":"P Jayaraman","year":"2007","unstructured":"Jayaraman, P. et al. Evidence for persistent, occult infection in neonatal macaques following perinatal transmission of simian-human immunodeficiency virus SF162P3. J. Virol. 81, 822\u2013834 (2007).","journal-title":"J. Virol."},{"key":"2444_CR18","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.144448","volume":"9","author":"MB Shapiro","year":"2024","unstructured":"Shapiro, M. B. et al. Immune perturbation following SHIV infection is greater in newborn macaques than in infants. JCI Insight 9, e144448 (2024).","journal-title":"JCI Insight"},{"key":"2444_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13972-y","volume":"11","author":"MB Shapiro","year":"2020","unstructured":"Shapiro, M. B. et al. Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity. Nat. Commun. 11, 70 (2020).","journal-title":"Nat. Commun."},{"key":"2444_CR20","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1128\/JVI.73.4.2947-2955.1999","volume":"73","author":"KKA van Rompay","year":"1999","unstructured":"van Rompay, K. K. A. et al. Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn rhesus macaques. J. Virol. 73, 2947\u20132955 (1999).","journal-title":"J. Virol."},{"key":"2444_CR21","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nm.4063","volume":"22","author":"AJ Hessell","year":"2016","unstructured":"Hessell, A. J. et al. Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques. Nat. Med. 22, 362\u2013368 (2016).","journal-title":"Nat. Med."},{"key":"2444_CR22","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1126\/science.285.5431.1261","volume":"285","author":"C Stahl-Hennig","year":"1999","unstructured":"Stahl-Hennig, C. et al. Rapid infection of oral mucosal-associated lymphoid tissue with simian immunodeficiency virus. Science 285, 1261\u20131265 (1999).","journal-title":"Science"},{"key":"2444_CR23","first-page":"2371","volume":"18","author":"JM Milush","year":"2004","unstructured":"Milush, J. M. et al. Rapid dissemination of SIV following oral inoculation. AIDS 18, 2371\u20132380 (2004).","journal-title":"AIDS"},{"key":"2444_CR24","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.4049\/jimmunol.1500527","volume":"196","author":"AJ Hessell","year":"2016","unstructured":"Hessell, A. J. et al. Achieving potent autologous neutralizing antibody responses against tier 2 HIV-1 viruses by strategic selection of envelope immunogens. J. Immunol. 196, 3064\u20133078 (2016).","journal-title":"J. Immunol."},{"key":"2444_CR25","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1086\/317918","volume":"183","author":"GC John","year":"2001","unstructured":"John, G. C. et al. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J. Infect. Dis. 183, 206\u2013212 (2001).","journal-title":"J. Infect. Dis."},{"key":"2444_CR26","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1016\/S2352-3018(23)00236-9","volume":"11","author":"D Persaud","year":"2024","unstructured":"Persaud, D. et al. HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1\/2 proof-of-concept study. Lancet HIV 11, e20\u2013e30 (2024).","journal-title":"Lancet HIV"},{"key":"2444_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piaf002","volume":"14","author":"CK Cunningham","year":"2025","unstructured":"Cunningham, C. K. et al. Safety, tolerability, and pharmacokinetics of long-acting broadly neutralizing HIV-1 monoclonal antibody VRC07-523LS in newborn infants exposed to HIV-1. J. Pediatr. Infect. Dis. Soc. 14, piaf002 (2025).","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"2444_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010396","volume":"18","author":"XL Chang","year":"2022","unstructured":"Chang, X. L. et al. Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody leronlimab in two species. PLoS Pathog. 18, e1010396 (2022).","journal-title":"PLoS Pathog."},{"key":"2444_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41586-025-09330-2","volume":"645","author":"A Ardeshir","year":"2025","unstructured":"Ardeshir, A. et al. Determinants of successful AAV-vectored delivery of HIV-1 bNAbs in early life. Nature 645, 1\u20139 (2025).","journal-title":"Nature"},{"key":"2444_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adw1976","volume":"18","author":"HL Wu","year":"2026","unstructured":"Wu, H. L. et al. Adeno-associated virus gene therapy-mediated CCR5 blockade suppresses virus replication long term in SHIV-infected macaques. Sci. Transl. Med. 18, eadw1976 (2026).","journal-title":"Sci. Transl. Med."},{"key":"2444_CR31","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s41564-025-02258-3","volume":"11","author":"BF Keele","year":"2026","unstructured":"Keele, B. F. et al. Initial sites of SIV rebound after antiretroviral treatment cessation in rhesus macaques. Nat. Microbiol. 11, 648\u2013663 (2026).","journal-title":"Nat. Microbiol."},{"key":"2444_CR32","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1128\/JVI.02447-13","volume":"88","author":"KKV Rompay","year":"2014","unstructured":"Rompay, K. K. V. et al. A vaccine against CCR5 protects a subset of macaques upon intravaginal challenge with simian immunodeficiency virus SIVmac251. J. Virol. 88, 2011\u20132024 (2014).","journal-title":"J. Virol."},{"key":"2444_CR33","doi-asserted-by":"publisher","first-page":"794638","DOI":"10.3389\/fimmu.2021.794638","volume":"12","author":"XL Chang","year":"2021","unstructured":"Chang, X. L. et al. CCR5 receptor occupancy analysis reveals increased peripheral blood CCR5+CD4+ T cells following treatment with the anti-CCR5 antibody leronlimab. Front. Immunol. 12, 794638 (2021).","journal-title":"Front. Immunol."},{"key":"2444_CR34","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1182\/blood-2016-08-735076","volume":"129","author":"RH Moy","year":"2017","unstructured":"Moy, R. H. et al. Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis. Blood 129, 906\u2013916 (2017).","journal-title":"Blood"},{"key":"2444_CR35","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1056\/NEJMoa1201248","volume":"367","author":"R Reshef","year":"2012","unstructured":"Reshef, R. et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N. Engl. J. Med. 367, 135\u2013145 (2012).","journal-title":"N. Engl. J. Med."},{"key":"2444_CR36","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.cell.2016.05.024","volume":"165","author":"Y Huang","year":"2016","unstructured":"Huang, Y. et al. Engineered bispecific antibodies with exquisite HIV-1-neutralizing activity. Cell 165, 1621\u20131631 (2016).","journal-title":"Cell"},{"key":"2444_CR37","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.clinthera.2024.08.019","volume":"46","author":"H Seethamraju","year":"2024","unstructured":"Seethamraju, H. et al. A randomized placebo-controlled trial of leronlimab in mild-to-moderate COVID-19. Clin. Ther. 46, 891\u2013899 (2024).","journal-title":"Clin. Ther."},{"key":"2444_CR38","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/infdis\/jiz532","volume":"222","author":"CK Cunningham","year":"2020","unstructured":"Cunningham, C. K. et al. Safety, tolerability, and pharmacokinetics of the broadly neutralizing human immunodeficiency virus (HIV)-1 monoclonal antibody VRC01 in HIV-exposed newborn infants. J. Infect. Dis. 222, 628\u2013636 (2020).","journal-title":"J. Infect. Dis."},{"key":"2444_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ymeth.2009.05.002","volume":"49","author":"JA Karl","year":"2009","unstructured":"Karl, J. A., Wiseman, R. W. & O\u2019Connor, D. H. Cost-effective sequence-based nonhuman primate MHC class I genotyping from RNA. Methods 49, 11\u201317 (2009).","journal-title":"Methods"},{"key":"2444_CR40","doi-asserted-by":"publisher","first-page":"12669","DOI":"10.1128\/JVI.02213-14","volume":"88","author":"RS Rudicell","year":"2014","unstructured":"Rudicell, R. S. et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J. Virol. 88, 12669\u201312682 (2014).","journal-title":"J. Virol."},{"key":"2444_CR41","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/nature10373","volume":"477","author":"LM Walker","year":"2011","unstructured":"Walker, L. M. et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466\u2013470 (2011).","journal-title":"Nature"},{"key":"2444_CR42","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/j.immuni.2023.04.019","volume":"56","author":"HL Wu","year":"2023","unstructured":"Wu, H. L. et al. Allogeneic immunity clears latent virus following allogeneic stem cell transplantation in SIV-infected ART-suppressed macaques. Immunity 56, 1649\u20131663.e5 (2023).","journal-title":"Immunity"},{"key":"2444_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50345-6","volume":"15","author":"D Malouli","year":"2024","unstructured":"Malouli, D. et al. Cytomegalovirus vaccine vector-induced effector memory CD4+ T cells protect cynomolgus macaques from lethal aerosolized heterologous avian influenza challenge. Nat. Commun. 15, 6007 (2024).","journal-title":"Nat. Commun."},{"key":"2444_CR44","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.chom.2022.07.013","volume":"30","author":"D Malouli","year":"2022","unstructured":"Malouli, D. et al. Cytomegalovirus-vaccine-induced unconventional T cell priming and control of SIV replication is conserved between primate species. Cell Host Microbe 30, 1207\u20131218.e7 (2022).","journal-title":"Cell Host Microbe"},{"key":"2444_CR45","doi-asserted-by":"publisher","first-page":"7588","DOI":"10.1128\/JVI.00734-12","volume":"86","author":"RM Lynch","year":"2012","unstructured":"Lynch, R. M. et al. The development of CD4 binding site antibodies during HIV-1 infection. J. Virol. 86, 7588\u20137595 (2012).","journal-title":"J. Virol."},{"key":"2444_CR46","doi-asserted-by":"publisher","first-page":"e99881","DOI":"10.1371\/journal.pone.0099881","volume":"9","author":"T Zhou","year":"2014","unstructured":"Zhou, T. et al. Transplanting supersites of HIV-1 vulnerability. PLoS ONE 9, e99881 (2014).","journal-title":"PLoS ONE"}],"container-title":["Nature Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41564-026-02444-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-026-02444-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-026-02444-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:03:31Z","timestamp":1792022611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41564-026-02444-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":46,"alternative-id":["2444"],"URL":"https:\/\/doi.org\/10.1038\/s41564-026-02444-x","relation":{},"ISSN":["2058-5276"],"issn-type":[{"value":"2058-5276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"assertion":[{"value":"18 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.G.H. and J.B.S. have a significant financial interest in CytoDyn, a company that may have a financial interest in the results of this research and technology. J.B.S. also serves on the scientific advisory board of CytoDyn. This potential individual conflict of interest has been reviewed and managed by Oregon Health & Science University. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}